FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Saturday

 

Roche Seeks to Mend Damaged Nerves in MS Push
























Image Source: BLOOMBERG

Roche Holding AG is seeking a partner with experimental drugs that might help repair the damage caused to the nervous system by MS -- considered a key step in managing the debilitating disease.

The Swiss drugmaker wants to find “compelling science” in what’s called remyelination, or repairing the protective sheath around nerve cells, according to Sanjay Keswani, the Basel-based head of neuroscience, opthalmology and rare diseases at Roche’s pharma research and early development group. Roche also has its own portfolio of experimental remyelination compounds, though none have reached human trials.

The world’s biggest maker of cancer therapies aims to expand its portfolio of MS treatments to tap into a market that’s projected to grow to $24 billion by 2020. Roche won its foothold in March, when it won U.S. approval for Ocrevus, a potential blockbuster that’s likely to be the only option for patients with a particular form of MS. In remyelination, Roche will have to catch up with Biogen Inc., which is already conducting human tests on its drug candidate.

“Frankly, we are currently looking at everything,” Keswani said in an interview on Tuesday. “What’s important for us is something that gets across the blood-brain barrier” and thus ensures a high concentration of the potential drug gets into the central nervous system, he said.

Biogen’s Lead

Biogen told analysts last month that it plans to start testing its compound opicinumab for remyelination in a mid-stage trial toward the end of the year. Other companies with remyelination projects that have leaped the hurdle from lab to human testing include U.S. biotech Acorda Therapeutics Inc., which has said it will seek a partner after test results later this year.

Roche in 2014 entered into a partnership with Inception Sciences Inc. and Versant Ventures to find and develop remyelination therapies.

Story Source: The above story is based on materials provided by BLOOMBERG
Note: Materials may be edited for content and length
Click here to read more


Go to Newer News Go to Older News